Our Therapeutic Antibody Discovery Platforms
Access a full suite of technologies that transform the transgenic animal approach to the discovery of fully human antibodies. Our antibody discovery platform includes the use of transgenic animals for antibody generation. Transgenic technology involves the use of genetically modified animals that have the ability to generate human antibodies. Our antibody and therapeutics programs include OmniRat, centered around the world’s only human lg-transgenic rats. Through the use of our transgenic animals for antibody discovery, we assist countless clients throughout the pharmaceutical and biotech spaces to develop treatments that improve patients’ lives.
Learn about our computationally powered antigen design platform for challenging therapeutic targets.
Robust high-throughput screening enables deep searches into immune repertoires to identify unique antibodies with a superior target profile.
Leverage the full suite of OmniAb technologies for enhanced discovery and optimization.
As one of the world’s leaders in antibody engineering & therapeutics, we leverage our technology and expertise to advance clinical drug development. The state-of-the-art transgenic animal technology we utilize gives our clients access to the most diverse antibody repertoires in the industry, as well as our cutting-edge screening technologies. We are the only company currently operating in this sector that provides multiple transgenic animal species, ranging from rats and mice to chickens and cows. The extent of our therapeutic antibody engineering capabilities makes us an ideal partner for research institutions and biopharmaceutical firms across the globe.
We partner closely with you to develop a plan that suits your specific requirements. To learn more about how the depth of our scientific knowledge can be put to work on your next project, reach out and speak with one of our representatives today.
Partnerships with Contract Research Organizations (CROs)
OmniAb works with a comprehensive network of international contract research organizations (CROs) with substantial experience generating OmniAb antibodies and with expertise in characterization, bioinformatics, cell line development, and GMP manufacturing. Current CROs include: